The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.

The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.

The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.

Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also described are pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such analogs or salts thereof, as well as methods, kits and uses thereof, for example for inducing or stimulating growth hormone secretion in a subject and for diagnosing, preventing or treating GH-deficient conditions in a subject.

Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also described are pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such analogs or salts thereof, as well as methods, kits and uses thereof, for example for inducing or stimulating growth hormone secretion in a subject and for diagnosing, preventing or treating GH-deficient conditions in a subject.

The invention relates to methods of treating stress-sensitive psychiatric diseases arising from trauma in a subject by enhancing ghrelin signaling in the BLA of the subject. The invention also relates to methods of reversing ghrelin resistance.

The invention relates to methods of treating stress-sensitive psychiatric diseases arising from trauma in a subject by enhancing ghrelin signaling in the BLA of the subject. The invention also relates to methods of reversing ghrelin resistance.

The present invention provides peptidomimetic macrocycles capable of modulating growth hormone levels and methods of using such macrocycles for the treatment of disease.

Provided herein are compositions and methods of use thereof for the treatment of metabolic disease such as diabetes and obesity. One embodiment provides a method of treating a metabolic disease or syndrome in a subject in need thereof by administering to the subject a therapeutically effective amount of a growth hormone releasing hormone (GHRH) antagonist or a pharmaceutical composition comprising the GHRH antagonist to reduce triglyceride-rich-lipoproteins (TRL) in the subject to treat the metabolic condition or syndrome.

Provided herein are compositions and methods of use thereof for the treatment of metabolic disease such as diabetes and obesity. One embodiment provides a method of treating a metabolic disease or syndrome in a subject in need thereof by administering to the subject a therapeutically effective amount of a growth hormone releasing hormone (GHRH) antagonist or a pharmaceutical composition comprising the GHRH antagonist to reduce triglyceride-rich-lipoproteins (TRL) in the subject to treat the metabolic condition or syndrome.